|Dr. Jeremy Max Levin||Chairman & CEO||754.15k||N/A||1953|
|Dr. Matthew J. During||Founder & Chairman of Scientific Advisory Board||669.93k||N/A||1957|
|Dr. Amit Rakhit||Chief Medical Officer and Head of R&D||668.71k||N/A||1970|
|Ms. Lora Pike||Sr. Director of Investor Relations & PR||N/A||N/A||N/A|
|Mr. Thomas Michael Perone||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||1965|
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Ovid Therapeutics Inc.’s ISS Governance QualityScore as of June 25, 2019 is 9. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.